Hp根治治疗对非酒精性脂肪性肝病患者血清细胞因子和血脂水平的影响

doi:10.3969/j.issn.1672-5069.2020.03.016

摘要/Abstract

摘要： 目的研究幽门螺杆菌(Hp)根治治疗对Hp阳性的非酒精性脂肪性肝病(NAFLD)患者血清炎性因子和脂质代谢的影响。方法 2015年6月～2019年6月我院收治的168例Hp阳性的NAFLD患者,采用随机数字表法分为两组,每组84例。给予对照组多烯磷脂酰胆碱胶囊和二甲双胍联合治疗,观察组在对照组治疗的基础上行标准的Hp根治治疗。采用放射免疫法测定血清肿瘤坏死因子α(TNF-α)水平,采用比色法测定血清超敏C反应蛋白(hs-CRP)水平,采用ELISA法测定白介素6(IL-6)和IL-8水平。采用放射免疫法测定空腹胰岛素(FINS),计算胰岛素抵抗指数(HOMA-IR)。结果在根治治疗1个月后,观察组Hp根除率为94.0%,而对照组无Hp转阴病例(P＜0.05);治疗后,观察组血清TNF-α水平为(12.6±2.5)ng/L,显著低于对照组【(28.6±5.5)ng/L,P＜0.05】,血清hs-CRP水平为(7.5±1.4)mg/L,显著低于对照组【(14.6±2.6)mg/L,P＜0.05】,血清IL-6水平为(12.5±2.3)ng/L,显著低于对照组【(29.6±5.4)ng/L,P＜0.05】,和血清IL-8水平为(80.4±23.7)ng/L,显著低于对照组【(145.2±38.1)ng/L,P＜0.05】;观察组TC为(3.1±0.9)mmol/L,显著低于对照组【(4.8±0.7)mmol/L,P＜0.05】,TG为(1.5±0.8)mmol/L,显著低于对照组【(2.9±0.7)mmol/L,P＜0.05】,LDL-C为(0.9±0.4)mmol/L,显著低于对照组【(1.7±0.5)mmol/L,P＜0.05】,而HDL-C为(2.4±0.3)mmol/L,显著高于对照组【(1.8±0.4)mmol/L,P＜0.05】;观察组FINS为(16.0±5.2)μIU/ml,显著低于对照组【(19.0±6.4)μIU/ml,P＜0.05】,HOMA-IR为(3.9±2.4),显著低于对照组【(4.4±3.1),P＜0.05】。结论根治Hp治疗对降低Hp阳性的NAFLD患者血清炎性因子水平、纠正糖脂代谢紊乱和改善肝功能具有重要的作用。

关键词: 非酒精性脂肪性肝病, 幽门螺杆菌感染, 炎性因子, 脂质代谢, 根治治疗

Abstract: Objective The aim of this study was to investigate the effect of radical treatment of Helicobacter pylori (Hp) on serum inflammatory factors and lipid metabolism in patients with Hp-positive nonalcoholic fatty liver disease (NAFLD). Methods 168 patients with Hp-positive NAFLD were enrolled to our hospital between June 2015 and June 2019, and were divided randomly into two groups, with 84 cases in each. The patients in control group received polyene phosphatidylcholine and metformin, while those in the observation group received standardized therapy for Hp eradication at the base of treatments in the control. Serum levels of tumor necrosis factor-alpha (TNF-alpha), hypersensitive C-reactive protein (hs-CRP), interleukin-6 (IL-6) and IL-8 were assayed, and fasting blood glucose (FPG), fasting insulin (FINS) and insulin resistance index (HOMA-IR) were also detected. Results At the end of one month after radical therapy, the eradication rate of Hp in the observation group was 94.0%, while no negative cases of Hp was found in the control (P<0.05); serum TNF-alpha in the observation group was (12.6±2.5) ng/L, significantly lower than , hs-CRP was (7.5±1.4) mg/L, significantly lower than , IL-6 was (12.5±2.3) ng/L, significantly lower than and serum IL-8 was (80.4±23.7) ng/L, significantly lower than in the control; blood total cholesterol level in the observation group was (3.1±0.9) mmol/L, significantly lower than , blood triglyceride was (1.5±0.8) mmol/L, significantly lower than , blood low density lipoprotein cholesterol was (0.9 ±0.4) mmol/L, significantly lower than , while blood high density lipoprotein cholesterol level was (2.4±0.3)mmol/L, significantly higher than【(1.8±0.4)mmol/L, P＜0.05】 in the control; serum FINS level in the observation group was (16.0±5.2) uIU/ml, significantly lower than , and HOMA-IR was (3.9±2.4), significantly lower than in the control. Conclusion Radical treatment of Hp might play an important role in reducing blood inflammatory factors, correcting the disorder of glycolipid metabolism and improving liver functions in Hp-positive NAFLD patients.

Key words: Nonalcoholic fatty liver diseases, Helicobacter pylori infection, Inflammatory factors, Lipid metabolism, Radical treatment

沈金勇,郭翔云,周辉,罗乐. Hp根治治疗对非酒精性脂肪性肝病患者血清细胞因子和血脂水平的影响[J]. 实用肝脏病杂志, 2020, 23(3): 364-367.

Shen Jingyong, Guo Xiangyun, Zhou Hui, et al. Effect of radical therapy forHelicobacter pylori on serum inflammatory factors and lipid metabolism in patients with Hp positive non-alcoholic fatty liver disease[J]. Journal of Practical Hepatology, 2020, 23(3): 364-367.

参考文献

[1] 钟燕, 苏淑婷, 宓余强. 非酒精性脂肪性肝病治疗研究进展. 实用肝脏病杂志, 2019, 22(1):150-153.
[2] Goni E, Franceschi F. Helicobacter pylori and extragastric diseases. Helicobacter, 2016, 21(S1):45-48.
[3] Vasapolli R, Malfertheiner P, Kandulski A. Helicobacter pylori and non-malignant upper gastrointestinal diseases. Helicobacter, 2016, 21(S1):30-33.
[4] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪肝专家委员会.非酒精性脂肪性肝病防治指南 (2018年版).实用肝脏病杂志,2018,21(2):177-186.
[5] 胡伏莲. 幽门螺杆菌感染诊疗指南. 北京:人民卫生出版社, 2013:14-25.
[6] Younossi ZM, Otgonsuren M, Henry L, et al. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009. Hepatology, 2016, 62(6):1723-1730.
[7]
[8] Kountouras J, Polyzos SA, Katsinelos P, et al. Helicobacter pylori in lean and obese patients with non-alcoholic fatty liver disease.Aliment Pharmacol Ther, 2017, 46(6):637-638.
[9] Salmanroghani H, Mirvakili M, Baghbanian M, et al. Efficacy and tolerability of two quadruple regimens: bismuth, omeprazole, metronidazole with amoxicillin or tetracycline as first-line treatment for eradication of helicobacter pylori in patients with duodenal ulcer: a randomized clinical trial. PLoS One, 2018, 13(6):96-106.
[10] Zhang W, Chen Q, Liang X, et al. Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-line Helicobacter pylori therapy. Gut, 2015, 64(11):1715-1720.
[11] Boyanova L, Evstatiev I, Yordanov D, et al. Three unsuccessful treatments of Helicobacter pylori, infection by a highly virulent strain with quadruple antibiotic resistance.Folia Microbiol, 2016, 61(4):307-310.
[12] Chan WK, Treeprasertsuk S, Imajo K, et al. Clinical features and treatment of nonalcoholic fatty liver disease across the Asia Pacific region-the GO ASIA initiative. Aliment Pharmacol Ther, 2018, 47(6):816-825.
[13] Vollmers HP, Dmmrich J, Ribbert H, et al. Human monoclonal antibodies from stomach carcinoma patients react with Helicobacter pylori and stimulate stomach cancer cells in vitro. Cancer, 2015, 74(5):1525-1532.
[14] Park JW, Lee, SH, Go du M, et al. Osteopontin depletion decreases inflammation and gastric epithelial proliferation during Helicobacter pylori infection in mice.Lab Invest, 2015, 95(6):660-671.
[15] Principi M, Iannone A, Losurdo G, et al. Nonalcoholic fatty liver disease in inflammatory bowel disease: prevalence and risk factors. Inflamm Bowel Dis, 2018, 24(7):1589-1596.
[16] Okushin K, Takahashi, Y, Yamamichi N, et al. Helicobacter pylori infection is not associated with fatty liver disease including non-alcoholic fatty liver disease: a large-scale cross-sectional study in Japan.BMC Gastroenterol, 2015, 15(1):25-34.
[17] Kim TJ, Sinn DH, Min YW, et al. A cohort study on helicobacter pylori infection associated with nonalcoholic fatty liver disease.J Gastroenterol, 2017, 52(11):1201-1210.
[18] Tsai KF, Liou JM, Chen MJ, et al. Distinct clinicopathological features and prognosis of helicobacter pylori negative gastric cancer. Gastroenterology, 2017, 12(2):52-63.
[19] Wijarnpreecha K, Thongprayoon, C, Panjawatanan, P, et al. Helicobacter pylori and risk of nonalcoholic fatty liver disease.J Clin Gastroenterol, 2018, 52(5):386-391.
[20] Yoshio S, Kazuyuki K, Shunsuke I, et al. Helicobacter pylori infection might have a potential role in hepatocyte ballooning in nonalcoholic fatty liver disease.J Gastroenterol, 2015, 50(9):996-1004.
[21] Potamitis GS, Axon AT. Helicobacter pylori and nonmalignant diseases. Helicobacter, 2015, 20(S1):26-29.